Company / Shareholders' Equity
Enliven Therapeutics, Inc. Shareholders' Equity History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$309.8M
FY2024
5-year range
-$76.8M / $309.8M
FY2020-FY2024
Trend
+26.0%
vs FY2023
Sector context
#127 of 213
Health Care
What the data says
At $310M, Enliven Therapeutics, Inc.'s shareholders' equity ranks #127 of 213 in the Health Care sector. Improved from -$77M to $310M over the past 2 years.
Based on SEC 10-K filings.
$310M in FY2024.
Improved from -$77M to $310M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#127 of 213 in Health CareTop 60% of 213This company $309.8M Sector average $2.5B
▼
-87.8% below sector average
Key checks
Key Insights
- In FY2024, shareholders' equity increased 26.0% year-over-year.
- Ranks #127 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $309.8M | +26.0% |
| FY2023 | $245.9M | +420.1% |
| FY2022 | -$76.8M | -79.1% |
| FY2021 | -$42.9M | -150.8% |
| FY2020 | $84.4M | +272.9% |
| FY2019 | -$48.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026